Heart failure drug trial offers continued access for patients
Disease control
ENROLLING_BY_INVITATION
This study gives people with pulmonary hypertension and heart failure continued access to an oral medication called levosimendan (TNX-103). It aims to track the safety of long-term use in 800 participants who previously received the drug in an earlier study. The main focus is mon…
Phase: PHASE3 • Sponsor: Tenax Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:08 UTC